ABCB1 structural models, molecular docking, and synthesis of new oxadiazolothiazin-3-one inhibitors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 694-698

  Rosano, Camillo ^a   Viale, Maurizio ^a   Cosimelli, Barbara ^b   Severi, Elda ^b   Gangemi, Rosaria ^a   Ciogli, Alessia ^c   De Totero, Daniela ^a   Spinelli, Domenico ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ABCB1 inhibitors; docking; drug design; LTCC blockers compounds; multidrug resistance; oxadiazolothiazin 3 ones

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; OXADIAZOLOTHIAZIN 3 ONE INHIBITOR; THIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CYTOFLUOROMETRY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULE; PRIORITY JOURNAL;

EID: 84881439292     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300436x     Document Type: Article

References (21)

1. Kourti, M.; Vavatsi, N.; Gombakis, N.; Sidi, V.; Tzimagiorgis, G.; Papageorgiou, T.; Koliouskas, D.; Athanassiadou, F. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia Int. J. Hematol. 2007, 86, 166-173
2. Hille, S.; Rein, D. T.; Riffelmann, M.; Neumann, R.; Sartorius, J.; Pfützner, A.; Kurbacher, C. M.; Schöndorf, T.; Breidenbach, M. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer Anticancer Drugs 2006, 17, 1041-1044
3. Takara, K.; Sakaeda, T.; Okumura, K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy Curr. Pharm. Des. 2006, 12, 273-286
4. Sharom, F. J. ABC multidrug transporters: structure, function and role in chemoresistance Pharmacogenomics 2008, 9, 105-127
5. Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system Physiol. Rev. 2006, 86, 1179-1236
6. 2+/ATP reveals a non-productive catalytic site J. Mol. Biol. 2006, 359, 940-949
7. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance Nat. Rev. Cancer 2005, 5, 275-284
8. Avendaño, C.; Menéndez, J. C. Inhibitors of multidrug resistance to antitumour agents (MDR) Curr. Med. Chem. 2002, 9, 159-193
9. Fischer, V.; Rodríguez-Gascón, A.; Heitz, F.; Tynes, R.; Hauck, C.; Cohen, D.; Vickers, A. E. The multidrug resistance modulator Valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite Drug Metab. Dispos. 1998, 26, 802-811
10. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58
11. Solary, E.; Drenou, B.; Campos, L.; de Crémoux, P.; Mugneret, F.; Moreau, P.; Lioure, B.; Falkenrodt, A.; Witz, B.; Bernard, M.; Hunault-Berger, M.; Delain, M.; Fernandes, J.; Mounier, C.; Guilhot, F.; Garnache, F.; Berthou, C.; Kara-Slimane, F.; Harousseau, J. L. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia Blood 2003, 102, 1202-1210
12. Van der Holt, B.; Löwenberg, B.; Burnett, A. K.; Knauf, W. U.; Shepherd, J.; Piccaluga, P. P.; Ossenkoppele, G. J.; Verhoef, G. E.; Ferrant, A.; Crump, M.; Selleslag, D.; Theobald, M.; Fey, M. F.; Vellenga, E.; Dugan, M.; Sonneveld, P. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood 2005, 106, 2646-2654
13. Nobili, S.; Landini, I.; Mazzei, T.; Mini, E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression Med. Res. Rev. 2012, 32, 1220-1262
14. Viale, M.; Cordazzo, C.; Cosimelli, B.; de Totero, D.; Castagnola, P.; Aiello, C.; Severi, E.; Petrillo, G.; Cianfriglia, M.; Spinelli, D. Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates J. Med. Chem. 2009, 52, 259-266
15. Viale, M. Multidrug resistance 1 gene (MDR1) SciBX 2009, 10.1038/scibx.2009.44
16. Schmitt, L.; Tampe, R. Affinity, specificity, diversity: a challenge for the ABC transporter TAP in cellular immunity ChemBioChem 2000, 1, 16-35
17. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R. P.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q. H.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-1722
18. Hemithioacetals 1 are stereochemically unstable, so recalling the well known situation observed in hemiacetals. At now, by dynamic NMR, the racemization barrier of some hemithioacetals 1 has been calculated as meaning the impracticability to isolate at room temperature the two relevant enantiomers (Cosimelli, B.; Mazzanti, A.; Spinelli, D.;).
19. Carosati, E.; Cruciani, G.; Chiarini, A.; Budriesi, R.; Ioan, P.; Spisani, R.; Spinelli, D.; Cosimelli, B.; Fusi, F.; Frosini, M.; Matucci, R.; Gasparrini, F.; Ciogli, A.; Stephens, P. J.; Devlin, F. J. Calcium channel antagonists discovered by a multidisciplinar approach J. Med. Chem. 2006, 49, 5206-5216
20. Stephens, P. J.; Devlin, F. J.; Gasparrini, F.; Ciogli, A.; Spinelli, D.; Cosimelli, B. Determination of the absolute configuration of a chiral oxadiazol-3-one calcium channel blocker, resolved using chiral chromatography, via concerted density functional theory calculations of its vibrational circular dichroism, electronic circular dichroism, and optical rotation J. Org. Chem. 2007, 72, 4707-4715
21. Ioan, P.; Ciogli, A.; Sirci, F.; Budriesi, R.; Cosimelli, B.; Pierini, M.; Severi, E.; Chiarini, A.; Cruciani, G.; Gasparrini, F.; Spinelli, D.; Carosati, E. Absolute configuration and biological profile of two thiazinooxadiazol-3-ones with L-type calcium channel activity: a study of the structural effects Org. Biomol. Chem. 2012, 10, 8994-9003